Curcumin suppresses colon cancer cell invasion via AMPK-induced inhibition of NF-κB, uPA activator and MMP9

Tong,Weihua; Wang,Quan; Sun,Donghui; Suo,Jian

doi:10.3892/ol.2016.5148

Curcumin suppresses colon cancer cell invasion via AMPK-induced inhibition of NF-κB, uPA activator and MMP9

Authors:
- Weihua Tong
- Quan Wang
- Donghui Sun
- Jian Suo
View Affiliations

Affiliations: Department of Gastrointestinal‑Colorectal Surgery, First Hospital of Jilin University, Changchun, Jilin 130021, P.R. China
Published online on: September 16, 2016 https://doi.org/10.3892/ol.2016.5148
Pages: 4139-4146

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Curcumin, an active nontoxic ingredient of turmeric, possesses potent anti‑inflammatory, antioxidant and anti-cancer properties; however, the molecular mechanisms of curcumin are not fully understood. The transcription factor nuclear factor-κB (NF‑κB) is key in cellular processes, and the expression/activation of urokinase‑type plasminogen activator (uPA) and matrix metalloproteinase‑9 (MMP9) are crucial for cell invasion. The present study investigated the hypothesis that curcumin inhibits colon cancer cell invasion by modulating NF‑κB‑mediated expression and activation of uPA and MMP9. Human colon cancer SW480 and LoVo cells were treated with various concentrations of curcumin. Curcumin was demonstrated to dose‑dependently inhibit the adhesion and proliferation ability of LoVo and SW480 cells using Transwell and MTT assays, respectively. In addition, curcumin activated 5' AMP‑activated protein kinase (AMPK) and suppressed p65 NF‑κB phosphorylation, as shown by western blot analysis. Compound C, a potent AMPK inhibitor, abolished curcumin‑induced inhibition of NF‑κB, uPA and MMP9, suggesting that AMPK activation is responsible for curcumin‑mediated NF‑κB, uPA and MMP9 inhibition. The binding activity of NF‑κB to DNA was examined and western blotting and quantitative polymerase reaction was performed to detect the effect of curcumin on the expression of uPA and MMP9. The present results revealed that curcumin significantly decreased the expression of uPA and MMP9 and NF‑κB DNA binding activity. Furthermore, curcumin decreased the level of the p65 subunit of NF‑κB binding to the promoter of the gene encoding uPA and MMP9, which suppressed transcriptional activation of uPA and MMP9. Overall, the present data suggest that curcumin inhibits colon cancer cell invasion via AMPK activation and subsequent inhibition of p65 NF‑κB, uPA and MMP9. The therapeutic potential of curcumin for colon cancer metastasis required additional study.

View Figures

View References

1	Fearon ER and Vogelstein B: A genetic model for colorectal tumorigenesis. Cell. 61:759–767. 1990. View Article : Google Scholar : PubMed/NCBI
2	Brooks SA, Lomax-Browne HJ, Carter TM, Kinch CE and Hall DM: Molecular interactions in cancer cell metastasis. Acta Histochem. 112:3–25. 2010. View Article : Google Scholar : PubMed/NCBI
3	Raghu H, Sodadasu PK, Malla RR, Gondi CS, Estes N and Rao JS: Localization of uPAR and MMP-9 in lipid rafts is critical for migration, invasion and angiogenesis in human breast cancer cells. BMC Cancer. 10:6472010. View Article : Google Scholar : PubMed/NCBI
4	Andreasen PA, Egelund R and Petersen HH: The plasminogen activation system in tumor growth, invasion, and metastasis. Cell Mol Life Sci. 57:25–40. 2000. View Article : Google Scholar : PubMed/NCBI
5	Vihinen P, Ala-aho R and Kähäri VM: Matrix metalloproteinases as therapeutic targets in cancer. Curr Cancer Drug Targets. 5:203–220. 2005. View Article : Google Scholar : PubMed/NCBI
6	Hildenbrand R, Gandhari M, Stroebel P, Marx A, Allgayer H and Arens N: The urokinase-system - role of cell proliferation and apoptosis. Histol Histopathol. 23:227–236. 2008.PubMed/NCBI
7	Andreasen PA, Kjøller L, Christensen L and Duffy MJ: The urokinase-type plasminogen activator system in cancer metastasis: A review. Int J Cancer. 72:1–22. 1997. View Article : Google Scholar : PubMed/NCBI
8	Visse R and Nagase H: Matrix metalloproteinases and tissue inhibitors of metalloproteinases: Structure, function, and biochemistry. Circ Res. 92:827–839. 2003. View Article : Google Scholar : PubMed/NCBI
9	Newell KJ, Witty JP, Rodgers WH and Matrisian LM: Expression and localization of matrix-degrading metalloproteinases during colorectal tumorigenesis. Mol Carcinog. 10:199–206. 1994. View Article : Google Scholar : PubMed/NCBI
10	Crowley CW, Cohen RL, Lucas BK, Liu G, Shuman MA and Levinson AD: Prevention of metastasis by inhibition of the urokinase receptor. Proc Natl Acad Sci USA. 90:5021–5025. 1993. View Article : Google Scholar : PubMed/NCBI
11	Roy R, Yang J and Moses MA: Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer. J Clin Oncol. 27:5287–5297. 2009. View Article : Google Scholar : PubMed/NCBI
12	Baichwal VR: Activate NF-kappa B or die? Curr Biol. 7:R94–R96. 1997. View Article : Google Scholar : PubMed/NCBI
13	Beg AA and Baltimore D: An essential role for NF-kappaB in preventing TNF-alpha-induced cell death. Science. 274:782–784. 1996. View Article : Google Scholar : PubMed/NCBI
14	Verma IM and Stevenson J: IkappaB kinase: Beginning, not the end. Proc Natl Acad Sci USA. 94:11758–11760. 1997. View Article : Google Scholar : PubMed/NCBI
15	Chen ZJ, Parent L and Maniatis T: Site-specific phosphorylation of IkappaBalpha by a novel ubiquitination-dependent protein kinase activity. Cell. 84:853–862. 1996. View Article : Google Scholar : PubMed/NCBI
16	Shishodia S and Aggarwal BB: Nuclear factor-kappaB activation: A question of life or death. J Biochem Mol Biol. 35:28–40. 2002. View Article : Google Scholar : PubMed/NCBI
17	Hatcher H, Planalp R, Cho J, Torti FM and Torti SV: Curcumin: From ancient medicine to current clinical trials. Cell Mol Life Sci. 65:1631–1652. 2008. View Article : Google Scholar : PubMed/NCBI
18	Aggarwal BB, Kumar A and Bharti AC: Anticancer potential of curcumin: Preclinical and clinical studies. Anticancer Res. 23:363–398. 2003.PubMed/NCBI
19	Singh S and Aggarwal BB: Activation of transcription factor NF-kappa B is suppressed by curcumin (diferuloylmethane) [corrected]. J Biol Chem. 270:24995–25000. 1995. View Article : Google Scholar : PubMed/NCBI
20	Kumar A, Dhawan S, Hardegen NJ and Aggarwal BB: Curcumin (Diferuloylmethane) inhibition of tumor necrosis factor (TNF)-mediated adhesion of monocytes to endothelial cells by suppression of cell surface expression of adhesion molecules and of nuclear factor-kappaB activation. Biochem Pharmacol. 55:775–783. 1998. View Article : Google Scholar : PubMed/NCBI
21	Shi M, Cai Q, Yao L, Mao Y, Ming Y and Ouyang G: Antiproliferation and apoptosis induced by curcumin in human ovarian cancer cells. Cell Biol Int. 30:221–226. 2006. View Article : Google Scholar : PubMed/NCBI
22	Kawamori T, Lubet R, Steele VE, Kelloff GJ, Kaskey RB, Rao CV and Reddy BS: Chemopreventive effect of curcumin, a naturally occurring anti-inflammatory agent, during the promotion/progression stages of colon cancer. Cancer Res. 59:597–601. 1999.PubMed/NCBI
23	Mukhopadhyay A, Bueso-Ramos C, Chatterjee D, Pantazis P and Aggarwal BB: Curcumin downregulates cell survival mechanisms in human prostate cancer cell lines. Oncogene. 20:7597–7609. 2001. View Article : Google Scholar : PubMed/NCBI
24	Bharti AC, Donato N and Aggarwal BB: Curcumin (diferuloylmethane) inhibits constitutive and IL-6-inducible STAT3 phosphorylation in human multiple myeloma cells. J Immunol. 171:3863–3871. 2003. View Article : Google Scholar : PubMed/NCBI
25	Kunnumakkara AB, Anand P and Aggarwal BB: Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancers through interaction with multiple cell signaling proteins. Cancer Lett. 269:199–225. 2008. View Article : Google Scholar : PubMed/NCBI
26	Plummer SM, Holloway KA, Manson MM, Munks RJ, Kaptein A, Farrow S and Howells L: Inhibition of cyclo-oxygenase 2 expression in colon cells by the chemopreventive agent curcumin involves inhibition of NF-kappaB activation via the NIK/IKK signalling complex. Oncogene. 18:6013–6020. 1999. View Article : Google Scholar : PubMed/NCBI
27	Mohan R, Sivak J, Ashton P, Russo LA, Pham BQ, Kasahara N, Raizman MB and Fini ME: Curcuminoids inhibit the angiogenic response stimulated by fibroblast growth factor-2, including expression of matrix metalloproteinase gelatinase B. J Biol Chem. 275:10405–10412. 2000. View Article : Google Scholar : PubMed/NCBI
28	Pan MH, Lin-Shiau SY and Lin JK: Comparative studies on the suppression of nitric oxide synthase by curcumin and its hydrogenated metabolites through down-regulation of IkappaB kinase and NFkappaB activation in macrophages. Biochem Pharmacol. 60:1665–1676. 2000. View Article : Google Scholar : PubMed/NCBI
29	Jobin C, Bradham CA, Russo MP, Juma B, Narula AS, Brenner DA and Sartor RB: Curcumin blocks cytokine-mediated NF-kappaB activation and proinflammatory gene expression by inhibiting inhibitory factor I-kappa B kinase activity. J Immunol. 163:3474–3483. 1999.PubMed/NCBI
30	Cheng AL, Hsu CH, Lin JK, Hsu MM, Ho YF, Shen TS, Ko JY, Lin JT, Lin BR, Ming-Shiang W, et al: Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res. 21:2895–2900. 2001.PubMed/NCBI
31	Al-Tubuly AA: SDS-PAGE and western blotting. Methods Mol Med. 40:391–405. 2000.PubMed/NCBI
32	Livak KI and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
33	Sandur SK, Deorukhkar A, Pandey MK, Pabón AM, Shentu S, Guha S, Aggarwal BB and Krishnan S: Curcumin modulates the radiosensitivity of colorectal cancer cells by suppressing constitutive and inducible NF-kappaB activity. Int J Radiat Oncol Biol Phys. 75:534–542. 2009. View Article : Google Scholar : PubMed/NCBI
34	Killeen SD, Wang JH, Andrews EJ and Redmond HP: Bacterial endotoxin enhances colorectal cancer cell adhesion and invasion through TLR-4 and NF-kappaB-dependent activation of the urokinase plasminogen activator system. Br J Cancer. 100:1589–1602. 2009. View Article : Google Scholar : PubMed/NCBI
35	Sliva D, English D, Lyons D and Lloyd FP Jr: Protein kinase C induces motility of breast cancers by upregulating secretion of urokinase-type plasminogen activator through activation of AP-1 and NF-kappaB. Biochem Biophys Res Commun. 290:552–557. 2002. View Article : Google Scholar : PubMed/NCBI
36	Tsunoda K, Kitange G, Anda T, Shabani HK, Kaminogo M, Shibata S and Nagata I: Expression of the constitutively activated RelA/NF-kappaB in human astrocytic tumors and the in vitro implication in the regulation of urokinase-type plasminogen activator, migration, and invasion. Brain Tumor Pathol. 22:79–87. 2005. View Article : Google Scholar : PubMed/NCBI
37	Bharti AC, Donato N, Singh S and Aggarwal BB: Curcumin (diferuloylmethane) down-regulates the constitutive activation of nuclear factor-kappa B and IkappaBalpha kinase in human multiple myeloma cells, leading to suppression of proliferation and induction of apoptosis. Blood. 101:1053–1062. 2003. View Article : Google Scholar : PubMed/NCBI
38	Zong H, Wang F, Fan QX and Wang LX: Curcumin inhibits metastatic progression of breast cancer cell through suppression of urokinase-type plasminogen activator by NF-kappa B signaling pathways. Mol Biol Rep. 39:4803–4808. 2012. View Article : Google Scholar : PubMed/NCBI
39	Shishodia S, Amin HM, Lai R and Aggarwal BB: Curcumin (diferuloylmethane) inhibits constitutive NF-kappaB activation, induces G1/S arrest, suppresses proliferation, and induces apoptosis in mantle cell lymphoma. Biochem Pharmacol. 70:700–713. 2005. View Article : Google Scholar : PubMed/NCBI
40	Shishodia S, Potdar P, Gairola CG and Aggarwal BB: Curcumin (diferuloylmethane) down-regulates cigarette smoke-induced NF-kappaB activation through inhibition of IkappaBalpha kinase in human lung epithelial cells: Correlation with suppression of COX-2, MMP-9 and cyclin D1. Carcinogenesis. 24:1269–1279. 2003. View Article : Google Scholar : PubMed/NCBI
41	Johnson SM, Gulhati P, Arrieta I, Wang X, Uchida T, Gao T and Evers BM: Curcumin inhibits proliferation of colorectal carcinoma by modulating Akt/mTOR signaling. Anticancer Res. 29:3185–3190. 2009.PubMed/NCBI
42	Chen H, Zhang ZS, Zhang YL and Zhou DY: Curcumin inhibits cell proliferation by interfering with the cell cycle and inducing apoptosis in colon carcinoma cells. Anticancer Res. 19:3675–3680. 1999.PubMed/NCBI
43	Baeuerle PA and Baichwal VR: NF-kappa B as a frequent target for immunosuppressive and anti-inflammatory molecules. Adv Immunol. 65:111–137. 1997. View Article : Google Scholar : PubMed/NCBI
44	Garg A and Aggarwal BB: Nuclear transcription factor-kappaB as a target for cancer drug development. Leukemia. 16:1053–1068. 2002. View Article : Google Scholar : PubMed/NCBI
45	Huang S, Pettaway CA, Uehara H, Bucana CD and Fidler IJ: Blockade of NF-kappaB activity in human prostate cancer cells is associated with suppression of angiogenesis, invasion, and metastasis. Oncogene. 20:4188–4197. 2001. View Article : Google Scholar : PubMed/NCBI
46	Hideshima T, Chauhan D, Richardson P, Mitsiades C, Mitsiades N, Hayashi T, Munshi N, Dang L, Castro A, Palombella V, et al: NF-kappa B as a therapeutic target in multiple myeloma. J Biol Chem. 277:16639–16647. 2002. View Article : Google Scholar : PubMed/NCBI
47	Ghosh S and Karin M: Missing pieces in the NF-kappaB puzzle. Cell. 109 Suppl:S81–S96. 2002. View Article : Google Scholar : PubMed/NCBI
48	Salminen A, Hyttinen JM and Kaarniranta K: AMP-activated protein kinase inhibits NF-kappaB signaling and inflammation: Impact on healthspan and lifespan. J Mol Med (Berl). 89:667–676. 2011. View Article : Google Scholar : PubMed/NCBI
49	Bai A, Ma AG, Yong M, Weiss CR, Ma Y, Guan Q, Bernstein CN and Peng Z: AMPK agonist downregulates innate and adaptive immune responses in TNBS-induced murine acute and relapsing colitis. Biochem Pharmacol. 80:1708–1717. 2010. View Article : Google Scholar : PubMed/NCBI
50	Yang Z, Kahn BB, Shi H and Xue BZ: Macrophage alpha1 AMP-activated protein kinase (alpha1AMPK) antagonizes fatty acid-induced inflammation through SIRT1. J Biol Chem. 285:19051–19059. 2010. View Article : Google Scholar : PubMed/NCBI
51	Sag D, Carling D, Stout RD and Suttles J: Adenosine 5′-monophosphate-activated protein kinase promotes macrophage polarization to an anti-inflammatory functional phenotype. J Immunol. 181:8633–8641. 2008. View Article : Google Scholar : PubMed/NCBI
52	Wang S, Zhang M, Liang B, Xu J, Xie Z, Liu C, Viollet B, Yan D and Zou MH: AMPKalpha2 deletion causes aberrant expression and activation of NAD(P)H oxidase and consequent endothelial dysfunction in vivo: Role of 26S proteasomes. Circ Res. 106:1117–1128. 2010. View Article : Google Scholar : PubMed/NCBI
53	Wu X, Mahadev K, Fuchsel L, Ouedraogo R, Xu SQ and Goldstein BJ: Adiponectin suppresses IkappaB kinase activation induced by tumor necrosis factor-alpha or high glucose in endothelial cells: Role of cAMP and AMP kinase signaling. Am J Physiol Endocrinol Metab. 293:E1836–E1844. 2007. View Article : Google Scholar : PubMed/NCBI
54	Hattori Y, Suzuki K, Hattori S and Kasai K: Metformin inhibits cytokine-induced nuclear factor kappaB activation via AMP-activated protein kinase activation in vascular endothelial cells. Hypertension. 47:1183–1188. 2006. View Article : Google Scholar : PubMed/NCBI
55	Cantó C and Auwerx J: AMP-activated protein kinase and its downstream transcriptional pathways. Cell Mol Life Sci. 67:3407–3423. 2010. View Article : Google Scholar : PubMed/NCBI
56	Zhong H, Voll RE and Ghosh S: Phosphorylation of NF-kappa B p65 by PKA stimulates transcriptional activity by promoting a novel bivalent interaction with the coactivator CBP/p300. Mol Cell. 1:661–671. 1998. View Article : Google Scholar : PubMed/NCBI